

# STUDY OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS DURING THE FOURTH QUARTER OF 2018 AND ANALYSIS OF ITS OFF-LABEL USE

S. Izquierdo Muñoz<sup>1</sup>, A. Pariente Junquera<sup>1</sup>, A. de Furtos Soto<sup>1</sup>  
<sup>1</sup>Hospital Pharmacy, Hospital Clínico Universitario. Valladolid.

## Backgrounds

The use of Intravenous immunoglobulins (IVIg) has increased due to its therapeutic usefulness in a great number of diseases. Despite this, IVIg label indications remain limited, so it is interesting to study their use off-label.

## Aim and objectives


To describe the use of IVIG in our hospital for three months and analyze if it has been used for labeled indications.

## Material and methods

Retrospective study (October-December 2018). Descriptive analysis of the use of immunoglobulins per patient and clinical indication. Information collected from the hospital's information systems and the computer records of the Farmatools<sup>®</sup> software.

## Results

89 patients



Average age: 61 years  
 (3 months-86,7 years)

The **dosage** used when IVIg was used as a replacement therapy

200-400 mg / kg every 3-5 weeks

The **dosage** used when IVIg was used for the rest of indications


1-2 g / kg in 2-5 days

Labeled indications

80% (71/89 patients)

Off-Labeled indications

20% (18/89 patients)



## Conclusion

The use of IVIG in indications unauthorized is frequent (20%), mainly in the field of neurology, which justifies the development of a protocol for the use of IVIG in this field for those indications with more scientific evidence and more common use: demyelinating neuropathies, myasthenia gravis and myopathies.

